Cancer drug sales power up Kelun-Biotech’s profit engine
The firm made more money from precision oncology treatments than from licensing deals in the first half, after gaining insurance coverage for its core drugs in China Key Takeaways: The…
INDUSTRY BRIEF: Trump eyes curbs on Chinese drugs, drawing industry pushback
The administration of U.S. President Donald Trump is weighing restrictions on the import of drugs and experimental therapies from China, a move that could disrupt the U.S. pharmaceutical industry and…
BRIEF: Abbisko moves into the black in 2024
Biopharmaceutical company Abbisko Cayman Ltd. (2256.HK) said on Monday that its revenue increased significantly last year, up from 19 million yuan ($2.59 million) in 2023 to 485 million yuan in…
WuXi Biologics sells vaccine plant as new U.S. law looms
The Chinese drug services giant built an Irish factory to produce vaccines for Merck, but has now opted to sell the plant to the U.S.-based multinational for $500 million Key…
Test results for new cancer drug take Akeso investors on wild ride
Shares in the Chinese pharmaceutical company swung back and forth as investors tried to make sense of clinical trial data for an immunotherapy drug billed as a potential world beater…
AstraZeneca pays hefty price for Chinese weight-loss drug
The drugs giant has licensed an experimental anti-obesity pill from China’s Eccogene as it tries to grab a chunk of the lucrative weight-loss market Key Takeaways: Chinese biotech Eccogene says…
CHINA BULLETIN: Europe Calls on China
In this week’s issue EU leaders come calling on China, Evergrande restructures and Airbus invests. On a scale of 1 to 10, we give the week a 5 for offshore-listed China stocks.
Recent Articles
RELATED ARTICLES
-
Jacobio Pharma poised to turn a profit from precision cancer drugs
-
TransThera completes late-stage trial enrollment for Tinengotinib cancer drug
2617.HK
- Mega licensing deal lifts 3SBio profits but core sales slip
-
Alphamab seals $2.2 billion licensing deal with AI biotech
9966.HK
- Insilico revenue soars above $100 million on AI drug partnerships
- A healthy return: drug spin-off nets Keymed up to $320 million
- Cancer screening company faces tough IPO test as market cools
